ASND (Ascendis Pharma AS) Growth Rank: 10 (As of Jul. 31, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASND Ascendis Pharma AS ASND
37 GF Score
Price $251.31
! 5 Warning Signs
View Full Analysis

What is Ascendis Pharma AS Growth Rank?

Ascendis Pharma AS ASND -0.29% 37 Growth Rank is 10 as of Jul. 31, 2026, which is at its 10-year median of 10.00. GuruFocus rates ASND with a GF Score™ of 37/100. The stock has 5 warning signs investors should review.

Ascendis Pharma AS has the Growth Rank of 10.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Ascendis Pharma AS Growth Rank Related Terms

ASND vs BBIO, JAZZ, EXEL: Growth Rank Comparison

For the Biotechnology subindustry, Ascendis Pharma AS's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ascendis Pharma AS Growth Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascendis Pharma AS's Growth Rank distribution charts can be found below:

* The bar in red indicates where Ascendis Pharma AS's Growth Rank falls into.


ASND
37GF Score
Ascendis Pharma AS ASND
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 10 mean?
Ascendis Pharma AS (ASND) has a Growth Rank of 10 as of Jul. 31, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Ascendis Pharma AS and its competitors. This is near median its historical median of 10.00. Over the past decade, Ascendis Pharma AS's Growth Rank has ranged from 10.00 to 10.00.
Is Ascendis Pharma AS's Growth Rank too high?
Ascendis Pharma AS's current Growth Rank of 10 is near median its 10-year median of 10.00. Over the past 10 years, this metric has ranged from a low of 10.00 to a high of 10.00. Overall, Ascendis Pharma AS has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Ascendis Pharma AS's Growth Rank compare to BBIO and JAZZ?
Ascendis Pharma AS's Growth Rank of 10 can be compared against companies in the Biotechnology industry. Historically, Ascendis Pharma AS's own Growth Rank has ranged from 10.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Biotechnology company?
A good Growth Rank depends on the Biotechnology industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Ascendis Pharma AS and its competitors. Ascendis Pharma AS's current Growth Rank is 10, which is near median its own 10-year median of 10.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascendis Pharma AS stock overvalued right now?
Ascendis Pharma AS (ASND) has a current Growth Rank of 10. The current Growth Rank is 10, which is near median its 10-year median of 10.00. Ascendis Pharma AS's overall GF Score™ is 37/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Ascendis Pharma AS (ASND), the current Growth Rank is 10 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ascendis Pharma AS Business Description

Other Exchanges A1SN34:Brazil
Address Tuborg Boulevard 12, Hellerup, DNK, 2900
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
37GF Score

Get the complete analysis for ASND

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$251.31
Price